Pegaptanib sodium for ocular vascular disease
Pegaptanib sodium (Macugen) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF)<sub> 165</sub> , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF<sub&g...
Main Authors: | Shukla Dhananjay, Namperumalsamy Perumalsamy, Goldbaum Mauro, Cunningham Jr Emmett |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2007-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2007;volume=55;issue=6;spage=427;epage=430;aulast=Shukla |
Similar Items
-
Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
by: Kiire CA, et al.
Published: (2015-12-01) -
CLINICAL OUTCOMES OF THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB
by: M. Burova, et al.
Published: (2015-12-01) -
Clinical outcomes of the treatment of exudative age-related macular degeneration with Pegaptanib
by: M. Burova, et al.
Published: (2013-02-01) -
Comparison of Ranibizumab and Pegabtanib Sodium Monotherapies in Terms of Rates of Stabilization After the First Three Doses
by: Nilüfer Koçak, et al.
Published: (2012-05-01) -
A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
by: Nagpal Manish, et al.
Published: (2007-01-01)